Osimertinib is commonly used for non-small cell lung cancer (NSCLC). The recommended dose is 80 mg once daily. As individual circumstances vary, the use of osimertinib should be strictly in accordance with the physician's instructions.
Indications for Osimertinib
(1) As adjuvant therapy for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, following complete tumor resection.
(2) First-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
(3) For adult patients with metastatic non-small cell lung cancer (NSCLC) who have EGFR T790M mutation-positive status, as detected by an FDA-approved test, and who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Dosage and Administration of Osimertinib
1. Usual Adult Dose for Non-Small Cell Lung Cancer
80 mg once daily.
2. Duration of Treatment
(1) Adjuvant therapy: Continue until disease progression, unacceptable toxicity, or for a maximum of 3 years.
(2) Metastatic lung cancer: Continue until disease progression or unacceptable toxicity.
Important Precautions for Osimertinib
1. Administration Timing
Take at a fixed time each day with a full glass of water. Osimertinib may be taken with or without food.
2. Precautions
The tablet should not be crushed, split, or chewed; however, if the patient is unable to swallow, it may be dispersed in water for administration.
3. Missed Dose
If a dose is missed, skip that dose and do not make up for it; take the next dose at the scheduled time.
4. Difficulty Swallowing
(1) For patients who have difficulty swallowing solids, the tablet may be dispersed in 60 mL (approximately 2 ounces) of non-carbonated water.
(2) Stir until the tablet breaks up into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation.
(3) Rinse the container with 120 mL to 240 mL (approximately 4 to 8 ounces) of water and drink immediately.
(4) If administration via a nasogastric tube is required, first disperse the tablet in 15 mL of non-carbonated water as described above, then transfer the remaining residue into a syringe with another 15 mL of water. Administer the resulting 30 mL liquid according to the nasogastric tube administration instructions, and flush with an appropriate amount of water (approximately 30 mL).
